EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS

Title:

EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS

Document Type and Number:

WIPO Patent Application WO/2022/251539

Kind Code:

A3

Abstract:

The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.

More Like This:

WO/2016/186071	OLIGOPEPTIDE HAVING PROINFLAMMATORY CYTOKINE SECRETION-INHIBITING ACTIVITY
JP2005537290	Bicyclopyrazoles active as kinase inhibitors, methods for producing them, and pharmaceutical compositions containing them.
JP2009532333	Heterobicyclic carboxamide as a kinase inhibitor

Inventors:

NASVESCHUK CHRISTOPHER (US)
DUPLESSIS MARTIN (US)
AHN JAE YOUNG (US)
HIRD ALEXANDER (US)
MICHAEL RYAN (US)
LAZARSKI KIEL (US)
LIANG YANKE (US)
JAESCHKE GEORG (CH)
RICCI ANTONIO (CH)
GOERGLER ANNICK (CH)
RUEHER DANIEL (CH)

Application Number:

PCT/US2022/031193

Publication Date:

January 05, 2023

Filing Date:

May 26, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

C4 THERAPEUTICS INC (US)

International Classes:

A61P35/04; A61K31/4184; C07D403/02

Domestic Patent References:

WO2020002487A1	2020-01-02
WO2017164887A1	2017-09-28
WO2021127561A1	2021-06-24

Attorney, Agent or Firm:

BELLOWS, Brent, R. et al. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: SENSOR ARRANGEMENTS FOR A SENSING GARMENT

Next Patent: MERCHANDISE DISPLAY SECURITY SYSTEMS AND METHODS